Pulmonary Sarcoidosis Pipeline Summary

DelveInsight’s, “Pulmonary Sarcoidosis - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pulmonary Sarcoidosis: Understanding

Pulmonary Sarcoidosis: Overview

Pulmonary sarcoidosis is a granulomatous inflammatory disease characterized by the formation of non-necrotizing granulomas, with a strong predilection for the lungs and intrathoracic lymph nodes. It is a multisystem disorder that can involve several organs, although pulmonary involvement represents the predominant manifestation. The clinical course is heterogeneous, ranging from asymptomatic disease with spontaneous radiographic remission to progressive pulmonary disease characterized by fibrosis, bronchiectasis, impaired lung function, and pulmonary hypertension. Radiographic disease is commonly classified using the Scadding staging system, with advanced stage IV disease associated with irreversible fibrotic changes and poorer outcomes.

The exact cause of pulmonary sarcoidosis remains unknown. Current understanding suggests that the disease develops through an abnormal immune response to one or more unidentified environmental or infectious antigens in genetically susceptible individuals. Proposed triggers include environmental exposures and microbial antigens, but no single causative agent has been established. The interaction between genetic susceptibility, environmental factors, and innate and adaptive immune responses is therefore considered important in disease development.

Pulmonary sarcoidosis is characterized by an exaggerated cellular immune response that results in the accumulation and activation of macrophages and T lymphocytes within the lungs. This immune activation promotes the release of inflammatory cytokines and chemokines, including tumor necrosis factor (TNF), and drives the formation of tightly organized non-necrotizing granulomas. Persistent granulomatous inflammation may resolve spontaneously in some patients, whereas failure to eliminate the underlying antigenic stimulus can result in chronic inflammation.

The diagnosis of pulmonary sarcoidosis is based on the integration of clinical, radiological, and histopathological findings, as there is no single diagnostic test that definitively establishes the disease. Chest radiography commonly demonstrates bilateral hilar lymphadenopathy, while high-resolution computed tomography (HRCT) can identify characteristic lymphadenopathy, peribronchovascular and upper-lobe abnormalities, pulmonary nodules, and the extent of fibrosis. Pulmonary function tests, including spirometry and diffusing capacity measurements, are used to assess pulmonary impairment and monitor disease progression.

Treatment of pulmonary sarcoidosis depends on disease severity, symptoms, pulmonary impairment, and evidence of progression, as some patients experience spontaneous remission and may be managed with observation. For symptomatic patients with pulmonary infiltrates and abnormal pulmonary function, oral glucocorticoids, particularly prednisone, are considered first-line therapy; the reviewed regimen describes an initial prednisone dose of approximately 20–40 mg/day, followed by tapering when clinical, pulmonary-function, and radiographic improvement occurs. Patients who require prolonged glucocorticoid therapy or develop treatment-related adverse effects may receive steroid-sparing immunosuppressive agents such as methotrexate or azathioprine.

"Pulmonary Sarcoidosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Sarcoidosis pipeline landscape is provided which includes the disease overview and Pulmonary Sarcoidosis treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Sarcoidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Sarcoidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Sarcoidosis.

Pulmonary Sarcoidosis Emerging Drugs Chapters

This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Sarcoidosis Emerging Drugs

• Efzofitimod: aTyr Pharma

Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Pulmonary Sarcoidosis.

Further product details are provided in the report……..

Pulmonary Sarcoidosis: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Sarcoidosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pulmonary Sarcoidosis

There are approx. 3+ key companies which are developing the therapies Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include, aTyr Pharma, and others.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Sarcoidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary Sarcoidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Sarcoidosis drugs.

Pulmonary Sarcoidosis Report Insights

• Pulmonary Sarcoidosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pulmonary Sarcoidosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pulmonary Sarcoidosis drugs?
• How many Pulmonary Sarcoidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Sarcoidosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Sarcoidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Sarcoidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• aTyr Pharma
• Xentria Inc.
• Meitheal Pharmaceuticals

Key Products

• Efzofitimod
• XTMAB 16